Previous 10 | Next 10 |
Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting Canada NewsWire HAMILTON, ON and BOSTON , March 5, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-...
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences Canada NewsWire HAMILTON, ON and BOSTON , Feb. 26, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radio...
2024-02-26 05:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-25 12:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Phase 3 data for As...
2024-02-19 13:31:25 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Buying call options is a lot like (American) football. Sometimes, you run the ball up the middle. And sometimes, you do a misdirection and run a bootleg. At their core, call options represe...
2024-02-16 09:31:30 ET More on Fusion Pharmaceuticals Investors growing more bullish on SMID cap biotech stocks Fusion issues pipeline update, says new plant now fully operational Seeking Alpha’s Quant Rating on Fusion Pharmaceuticals Historical earnin...
Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy Canada NewsWire FPI-2265 positioned to be the first approved PSMA targeted alpha therapy HAMILTON, ON ...
Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference Canada NewsWire HAMILTON, ON and BOSTON , Feb. 7, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on devel...
2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...
2024-01-26 09:15:02 ET Wedbush analyst issues STRONG BUY recommendation for FUSN on January 26, 2024 09:00AM ET. The previous analyst recommendation was Strong Buy. FUSN was trading at $11.01 at issue of the analyst recommendation. The overall analyst consensus : HOLD. ...
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
Fusion Pharmaceuticals Inc. Website:
Acquisition of Fusion Pharmaceuticals Completed Canada NewsWire HAMILTON , ON and BOSTON , June 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), a...
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Canada NewsWire HAMILTON , ON and BOSTON , May 31, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Canada NewsWire HAMILTON, ON and BOSTON , May 29, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiocon...